Opportunity timeline
In plain English
Los Alamos National Laboratory is offering licensing opportunities for its NanoFiber Engineered Therapeutics Platform (NanoFET), a modular nanofiber scaffold for developing immunotherapies, vaccines, and biodefense treatments. The platform uses interchangeable nanobodies and peptides, supports multivalent targeting, and is at technology readiness level 3. U.S. patent application LA-UR-26-25007 is pending; exclusive and non-exclusive licenses may be available to existing and startup companies. This is not a request for outside development services.
About this opportunity
NanoFiber Engineered Therapeutics Platform (NanoFET) from Los Alamos National Laboratory offers pharmaceutical and biodefense organizations a modular, adaptable scaffold for building next-generation immunotherapies. By merging self-assembling peptide nanofibers with interchangeable nanobody and peptide components, the platform enables rapid development of targeted treatments that bridge disease agents directly to the patient’s own immune cells. Infectious diseases and chronic conditions such as cancer continue to impose enormous public health and economic burdens worldwide. Conventional vaccines and biologics are typically designed against a single pathogen or target, leaving populations…
Time remaining
Closes Dec 18, 2026
Related Opportunities

DARPA Surgical Competition (DSC) Industry Day

Cryo-Electron Microscopy (Cryo-EM) Services

Human Hindbrain Organoid Functional Assay Services.

Chemical, Biological, Radiological and Nuclear Advance Defense Enabling Network and Clinical Capability (CADENCC)

Study entitled “Malaria and vector borne disease surveillance in the Colombia/Venezuela border”
Bid details are gathered and summarized automatically. Please verify details at the original source.
Ref No.
BS-59C11B

